The Indian pharma secondary sales (sales made by the distributor to chemists) facts for the month of April hints sturdy buoyancy in the market.
The value growth for the nation’s pharmaceutical market stayed strong for the third successive month, registering an increase of 18.2% during April.
Growth for the May last year to April this year period augmented to 16% from 15.2% growth in April 2011 to March 2012 period.
Pharmaceutical market research firm, AIOCD AWACS, accumulated the facts.
Trends in growth hint that large-cap firms originated slower than the market, with the exception of Zydus Cadila (19.2%). Ranbaxy grew 17.8% in the month, Torrent and Novartis' sales surged 17.7% with Sun directly accompanying them at 17.6%, and Lupin recording 15.6% increase.
On the contrary, Glenmark saw a stellar development of 35.9% for the month.
Other pharma giants that surpassed the market in the month comprise Pfizer (30.9%); Glaxo (23.8%); IPCA (20.6%); Wockhardt (19.8%).
Dr Reddy's registered a lukewarm 9% increase, whilst Unichem saw slowest growth among listed firms with a small 4.4% development.
Anti-diabetic (29.2%), anti-neoplastic (22.3%) and cardiology (21%) were the best ever rising therapy sections, whereas anti-malarials (10.3%), vaccines (10.6%) and anti-infectives (11.8%) were the major laggards.
Among the therapy sections, it was chronic therapies that outperformed the market.